Therefore, we next explored if fusions were associated with a previously validated genomic signature associated with CRC progression on prior anti-EGFR therapies, because treatment histories were not available for the entire fusion cohort.16,29. The gene discussed is EGFR; the disease is colorectal carcinoma.